Endo Oc Vs Injectable

---
name: endo-oc-vs-injectable
description: Suggests oral contraceptives over injectable contraceptives for women with BMI ≥27 kg/m2 with comorbidities or BMI ≥30 kg/m2 seeking contraception, provided they are well‑informed and oral contraceptives are not contraindicated. Triggers include clinician questions such as “Which contraceptive method is less likely to cause weight gain in this obese patient?” or “Should I recommend oral pills instead of depot injection for this patient with BMI 29 and hypertension?”.
---

# Prefer oral contraceptives over injectable for women with BMI thresholds seeking contraception

## STEP 1 — Gather Information
Collect patient’s BMI, presence of obesity‑related comorbidities (e.g., hypertension, diabetes, dyslipidemia), contraceptive goals, and screen for contraindications to oral contraceptives (VTE/thrombophilia, uncontrolled hypertension ≥160/100 mmHg, migraine with aura, active liver disease, breast cancer, pregnancy). Confirm the patient is well‑informed about risks and benefits of both methods.

## STEP 2 — Rule In / Rule Out
Determine if the patient meets BMI criteria: BMI ≥27 kg/m2 with at least one comorbidity **OR** BMI ≥30 kg/m2. If **yes**, proceed to Step 3; if **no**, consider other contraceptive options per usual care (this pathway does not apply).

## STEP 3 — Classify or Stratify
Assess whether oral contraceptives are medically safe (no contraindications) and the patient is well‑informed. If both are true, classify as a candidate for preferring oral contraceptives; if any contraindication exists or the patient declines after counseling, classify as unsuitable for this recommendation.

## STEP 4 — Decide
For candidates, recommend oral contraceptives (combined hormonal pill, patch, or ring) over injectable depot medroxyprogesterone acetate, engage in shared decision‑making, and document the discussion. For unsuitable candidates, discuss alternative contraceptive methods (e.g., progestin‑only pill, IUD, barrier) based on individual risk‑benefit profile.

## Clinical Guardrails / Mimics / Pitfalls
Do not prescribe estrogen‑containing oral contraceptives in patients with VTE/thrombophilia, uncontrolled hypertension, migraine with aura, active liver disease, or breast cancer. Avoid assuming all obese patients desire weight‑neutral contraception; elicit patient preferences. Recognize that injectable depot medroxyprogesterone may cause weight gain and bone mineral density loss; counsel accordingly. Do not overlook non‑hormonal options when hormonal methods are contraindicated.

## Concrete Clinical Example
A 34‑year‑old woman with BMI 28 kg/m2 and hypertension seeks contraception, has no personal or family history of VTE, normal liver tests, and is well‑informed about options. She expresses concern about weight gain. Recommend a combined oral contraceptive pill after confirming no contraindications, and discuss monitoring blood pressure.

**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Apovian et al., 2015, doi:10.1210/jc.2014-3415